In hindsight it was a good move but I'm quite sure this failure came as a big surprise to management and it sets back two (or perhaps more) programs. The plan was to input the 1404 data and create an A.I. database geared towards personalized therapy. They have a team working on this. This indicated a high level of confidence going into 1404 results. Will we see poor or mixed results with PYL?
“I am a big believer in giving it all away and have always said that the best financial planning ends with bouncing the check to the undertaker.”
Mike Bloomberg
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM